Trial Profile
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary) ; Prednisolone
- Indications Churg-Strauss syndrome
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline; GSK
- 26 Feb 2024 Long term safety results of Mepolizumab presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 14 Feb 2024 The protocol has been amended as above-1) Number of actual number of patients has been changed from 101 to 100. 2) Primary endpoint has been amended.
- 17 Jan 2024 Status changed from active, no longer recruiting to completed.